Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial.
Qiang Lv, Chen Chen, Ling Lin, Xianming Zhao, Junhong Chen, Zijing Liang, Yanfen Chai, Bo Du, Lei Sun, Xiaoliang Chen, Min Liu, Xiwen Zhang, Zhanwei Cao, Hongwei Zhang, Dexiong Chen, Zhifang Wang, Yiming Zhong, Jiaying Zhu, Feng Gao, Xifu Wang, Gaoxing Zhang, Lipeng Li, Jinxia Ma, Min Zhao, Yanhong Ouyang, Shubin Guo, Hengliang Wang, Ping Yang, Ruili He, Zhichen Zhao, Liming Sun, Lidong Wu, Yanqing Wu, Xianxia Liu, Tie Xu, Na Li, Tianyi Zhu, Changsheng Ma
J Hypertens 44(1) 204-210
摘要
摘要
BACKGROUND: Clevidipine emulsion injection is an ultra-short-acting, intravenous calcium-channel blocker that produces a rapid and transient antihypertensive effect. METHODS: This is a multicenter, randomized, single-blind, parallel, positive-controlled, noninferiority phase III clinical trial comparing the efficacy and safety of clevidipine and nicardipine in hypertensive emergencies. Participants were randomly assigned in a 1 : 1 ratio to the experimental group (clevidipine emulsion injection) or the positive-control group (nicardipine), and standard safety data were collected. RESULTS: In the per-protocol set (PPS), the primary endpoint showed that 100.0% of patients in the clevidipine group achieved a 15-25% reduction in systolic blood pressure from baseline within 30 min after dosing, compared with 95.9% in the nicardipine group. The absolute difference between the two proportions was 4.1% [95% confidence interval (CI): 0.58, 7.62], with the lower bound exceeding the noninferiority margin of -10%. Secondary endpoints revealed that the median time to reach the target systolic blood pressure (defined as a 15-25% reduction from baseline) was 9.0 (9.0, 12.0) minutes for clevidipine versus 12.0 (12.0, 15.0) minutes for nicardipine, and the between-group difference was statistically significant ( P < 0.0001). The proportions of patients who successfully transitioned to oral antihypertensive therapy within 6 h after study drug discontinuation were 96.83% for clevidipine and 95.90% for nicardipine, with no statistically significant difference ( P = 0.7459). In the safety set (SS), the safety endpoint showed that the proportion of patients whose systolic blood pressure fell by >25% from baseline within 3 min after dosing was 0.00% for clevidipine and 0.79% for nicardipine, with no statistically significant difference ( P = 0.4980). The overall incidence of adverse events was similar between clevidipine and nicardipine. CONCLUSIONS: Clevidipine has similar therapeutic effects and safety compared with the nicardipine. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04670809.
KM 提取结果
0 个 Figure · 0 个 KM 面板